ALLRNasdaqPharmaceutical PreparationsFiscal year ends December 31

Allarity Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$0.87−0.02 (-2.46%)

Close on Oct 19, 2026

Market cap: $13.89M
P/E (TTM): –
Dividend yield: –

Allarity Therapeutics, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Revenue	0.32	0	–	–	–	–
Gross Profit	–	–	–	-2.27	–	–
Research & Development	6.60	6.10	7.10	6.93	14	4.22
General & Administrative	6.32	11	10	9.96	12	4.10
Operating Expenses	13	27	17	34	27	8.32
Operating Income	-13	-27	-17	-34	-27	-8.32
Interest Expense	0.19	0.65	0.50	0.22	0.10	0.09
Interest & Investment Income	0.80	0.53	0.02	0.03	–	–
Other Non-Operating Income	1.37	2.35	5.31	17	0.04	1.90
Asset Impairment Charges	–	–	–	3.56	–	–
Gain (Loss) on Investments	–	–	–	-0.12	-0.50	0.71
Pretax Income	-11	-25	-12	-18	–	–
Income Tax Expense	0	-0.38	0.08	-1.52	0.13	0.20
Net Income incl. Noncontrolling Interests	–	–	–	-16	-27	-6.62
Minority Interest in Earnings	–	–	–	–	–	-0.02
Net Income	-11	-25	-12	-16	-27	-6.62
Preferred Dividends	–	–	0.12	1.57	–	–
Net Income to Common	-11	-25	-20	-21	-27	-6.62
EPS (Basic)(per share)	-0.78	-15.65	-6,031.31	-3,093.42	-146.65	-71.05
EPS (Diluted)(per share)	–	–	-10.26	-3,093.42	-146.65	–
Shares Outstanding (Basic, Weighted)(shares)	14	1.61	0.00	0.01	0.18	0.09
Shares Outstanding (Diluted, Weighted)(shares)	14	1.61	1.99	0.01	0.18	0.09
EBITDA	–	-27	-17	-34	-26	-8.27
Net Interest Income	–	–	–	–	-1.35	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: –
Operating margin: -3373.4%
Net margin: -3854.4%
Return on equity, FY2025: -103.8%

Financial strength

Current ratio: 1.11
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 59.4%

Valuation

P/E ratio: –
Price to sales: 43.41
Price to book: 3.93
Dividend yield: –